<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076321</url>
  </required_header>
  <id_info>
    <org_study_id>1207111</org_study_id>
    <nct_id>NCT02076321</nct_id>
  </id_info>
  <brief_title>The Effect of NSAID Use in the Acute Phase of Skeletally Immature Bone Healing: A Prospective Study</brief_title>
  <official_title>The Effect of NSAID Use in the Acute Phase of Skeletally Immature Bone Healing: A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <brief_summary>
    <textblock>
      Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, are excellent medications&#xD;
      for providing pain control in children with fractures or those who have surgery to correct&#xD;
      bony deformity requiring the bone to be cut (osteotomy) and realigned. There is some data to&#xD;
      suggest that these types of medications can adversely affect bone healing in adult patients&#xD;
      with broken bones or those having spine fusion surgery. There is little data with regard to&#xD;
      how these medications effect bone healing in children. With this project, the investigators'&#xD;
      goal is to determine if NSAIDs delay or otherwise adversely effect bone healing and to&#xD;
      demonstrate that these medications adequately control pain in children with broken bones or&#xD;
      those who have had an osteotomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-steroidal anti-inflammatory drugs (NSAIDs) are effective in controlling both&#xD;
      post-operative pain and pain associated with orthopaedic injuries, particularly in the&#xD;
      pediatric population. Additionally, use of NSAIDs for pain control in this setting avoids the&#xD;
      use of narcotic pain medications, the adverse effects of which are well known.&#xD;
&#xD;
      Recent research has suggested a possible association between use of NSAIDs and impaired&#xD;
      fracture healing in the skeletally mature, or adult, population. Several adult mammal studies&#xD;
      have demonstrated inhibition of bony repair with administration of NSAIDs. Yet, other adult&#xD;
      animal studies have failed to find the same effect. Clinical data in the adult population is&#xD;
      similarly conflicted, with some studies showing an inhibition of bone healing after posterior&#xD;
      spinal fusion, while a larger study found no correlation. The data investigating the effects&#xD;
      of NSAID use in adults after fracture or osteotomy is even less clear with some studies&#xD;
      demonstrating higher rates of non-union with NSAID administration and others finding no&#xD;
      significant effect on bone healing.&#xD;
&#xD;
      The research investigating these outcomes in the skeletally immature population is limited;&#xD;
      one study compared administration of ketorolac versus normal saline for 7, 14 and 21 days in&#xD;
      a juvenile rat model with a stabilized tibia fracture. They found no significant difference&#xD;
      in strength, stiffness or histological characteristics of fracture callus between the two&#xD;
      groups. Clinical retrospective studies of the pediatric population with regard to use of&#xD;
      NSAIDs after posterior spinal fusion have failed to reproduce findings of inhibitory effects&#xD;
      on bone healing. Similarly, two retrospective studies found no cases of delayed union or&#xD;
      non-union in pediatric patients who received perioperative ketorolac around the time of&#xD;
      operative fixation of fractures, or osteotomy. Given these results, the way in which and the&#xD;
      degree to which NSAIDs perturb the inflammatory mileu during the acute phase of healing is&#xD;
      potentially distinct from the effects on bone healing in the skeletally mature.&#xD;
&#xD;
      There have been no clinical prospective, randomized studies to evaluate the effect, if any,&#xD;
      that NSAIDs have on bone healing in the skeletally immature patient population. The&#xD;
      investigators hypothesize that NSAID administration in the acute phase of bone healing,&#xD;
      whether it be a fracture or osteotomy, will not result in delayed union or non-union as&#xD;
      compared to patients who take acetaminophen for pain control during this same time period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the Time to Union of Fractures and Osteotomies in Skeletally Immature Patients Administered NSAIDs for Pain Control, Versus Those Administered Acetaminophen for Pain Control.</measure>
    <time_frame>The subject will be enrolled/assessed up to 6 months post-injury/osteotomy.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Fractures</condition>
  <arm_group>
    <arm_group_label>Acetaminophen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSAID (Ibuprofen)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).</description>
    <arm_group_label>Acetaminophen</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.</description>
    <arm_group_label>NSAID (Ibuprofen)</arm_group_label>
    <other_name>Advil</other_name>
    <other_name>Motrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Male aged 16 years or less or female aged 14 years or less&#xD;
&#xD;
               -  Open physis on radiographs&#xD;
&#xD;
               -  Fracture undergoing closed treatment or operative treatment or patient undergoing&#xD;
                  elective osteotomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Regular use of NSAIDs&#xD;
&#xD;
               -  Allergy to NSAIDs&#xD;
&#xD;
               -  Inability to take breakthrough medications due side effects or allergy&#xD;
&#xD;
               -  Systemic illness&#xD;
&#xD;
               -  Renal impairment&#xD;
&#xD;
               -  Liver disease&#xD;
&#xD;
               -  Polytrauma&#xD;
&#xD;
               -  Uncontrolled diabetes&#xD;
&#xD;
               -  Regular use of corticosteroids&#xD;
&#xD;
               -  History of any skeletal dysplasia&#xD;
&#xD;
               -  History of neuromuscular disorder&#xD;
&#xD;
               -  History of bleeding disorder&#xD;
&#xD;
               -  History of liver disorder&#xD;
&#xD;
               -  Pathologic fracture&#xD;
&#xD;
               -  Closed physes&#xD;
&#xD;
               -  Male greater than 16 years old&#xD;
&#xD;
               -  Female greater than 14 years old&#xD;
&#xD;
               -  Pregnant or possibly pregnant females based on report and last menstrual period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel G Hoernschemeyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Missouri Health System</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 19, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <results_first_submitted>January 22, 2018</results_first_submitted>
  <results_first_submitted_qc>March 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2018</results_first_posted>
  <last_update_submitted>February 13, 2019</last_update_submitted>
  <last_update_submitted_qc>February 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Daniel Hoernschemeyer</investigator_full_name>
    <investigator_title>Orthopaedic Surgeon</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acetaminophen</title>
          <description>control group&#xD;
Acetaminophen: acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).</description>
        </group>
        <group group_id="P2">
          <title>NSAID (Ibuprofen)</title>
          <description>Study group&#xD;
Ibuprofen: ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acetaminophen</title>
          <description>control group&#xD;
Acetaminophen: acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).</description>
        </group>
        <group group_id="B2">
          <title>NSAID (Ibuprofen)</title>
          <description>Study group&#xD;
Ibuprofen: ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.44" lower_limit="2" upper_limit="16"/>
                    <measurement group_id="B2" value="7.67" lower_limit="1.5" upper_limit="16"/>
                    <measurement group_id="B3" value="7.56" lower_limit="1.5" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Compare the Time to Union of Fractures and Osteotomies in Skeletally Immature Patients Administered NSAIDs for Pain Control, Versus Those Administered Acetaminophen for Pain Control.</title>
        <time_frame>The subject will be enrolled/assessed up to 6 months post-injury/osteotomy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen</title>
            <description>control group&#xD;
Acetaminophen: acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).</description>
          </group>
          <group group_id="O2">
            <title>NSAID (Ibuprofen)</title>
            <description>Study group&#xD;
Ibuprofen: ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Compare the Time to Union of Fractures and Osteotomies in Skeletally Immature Patients Administered NSAIDs for Pain Control, Versus Those Administered Acetaminophen for Pain Control.</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" lower_limit="22" upper_limit="84"/>
                    <measurement group_id="O2" value="40.5" lower_limit="19" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Acetaminophen</title>
          <description>control group&#xD;
Acetaminophen: acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).</description>
        </group>
        <group group_id="E2">
          <title>NSAID (Ibuprofen)</title>
          <description>Study group&#xD;
Ibuprofen: ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Hoernschemeyer</name_or_title>
      <organization>University of Missouri, Department of Orthopaedics</organization>
      <phone>(573)882-1351</phone>
      <email>hoernschemeyerd@health.missouri.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

